# Data Sheet (Cat.No.T11827)

TargetMol

## Pradigastat

### Chemical Properties



| | |
|---|---|
| CAS No. : | 956136-95-1 |
| Formula: | C25H24F3N3O2 |
| Molecular Weight: | 455.47 |
| Appearance: | no data available |
| Storage: | store at low temperature<br>Powder: -20°C for 3 years \| In solvent: -80°C for 1 year |

### Biological Description

| | |
|---|---|
| Description | Pradigastat (LCQ-908) is an orally active, potent and selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor for the treatment of constipation, which may be used in the study of obesity and diabetes. |
| Targets(IC50) | Transferase |
| In vitro | Pradigastat inhibits BCRP-mediated efflux activity in BCRP-overexpressing human ovarian cancer cell lines in a dose-dependent manner, with an IC50 value of 5 μM. Similarly, pradigastat demonstrates concentration-dependent inhibition of OATP1B1, OATP1B3 (estradiol 17β-glucuronide transport), and OAT3 (sulfated estrone-3-sulfate transport), with estimated IC50 values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively.3]. |
| In vivo | Research indicates that Pradigastat (LCQ-908) can inhibit postprandial triglyceride levels in rats, dogs, and monkeys. In rats with eliminated lipoprotein lipase (LPL) activity, Pradigastat reduces postprandial plasma triglyceride accumulation. Additionally, Pradigastat lowers the rate of postprandial chylomicron triglyceride (CM-TG) secretion into the lymphatic system and decreases chylomicron particle size[2]. |

### Solubility Information

| | |
|---|---|
| Solubility | H2O: <0.1 mg/mL (Insoluble)<br>DMSO: 50 mg/mL (109.78 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.1955 mL | 10.9777 mL | 21.9553 mL |
| 5 mM | 0.4391 mL | 2.1955 mL | 4.3911 mL |
| 10 mM | 0.2196 mL | 1.0978 mL | 2.1955 mL |
| 50 mM | 0.0439 mL | 0.2196 mL | 0.4391 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Meyers CD, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015 Feb 18;14:8.
Charles DanielMeyersMD, et al. The DGAT1 inhibitor pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans. Journal of Clinical Lipidology. Volume 7, Issue 3, May-June 2013, Page 285.
Kulmatycki K, et al. Evaluation of a potential transporter-mediated drug interaction between ZD 4522 and pradigastat, a novel DGAT-1 inhibitor. Int J Clin Pharmacol Ther. 2015 May;53(5):345-55.





Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481